Form 8-K - Current report:
SEC Accession No. 0001171843-25-001020
Filing Date
2025-02-24
Accepted
2025-02-24 07:06:01
Documents
15
Period of Report
2025-02-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_022425.htm   iXBRL 8-K 17087
2 PRESS RELEASE exh_991.htm EX-99.1 115907
  Complete submission text file 0001171843-25-001020.txt   347268

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3003
4 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25598
5 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
6 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
17 EXTRACTED XBRL INSTANCE DOCUMENT f8k_022425_htm.xml XML 3299
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 25654167
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)